Cargando…

Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis

BACKGROUND: Tumor markers are useful for detection and preoperative evaluation of ovarian tumors. We evaluated the clinical usefulness of cancer antigen (CA) 125, human epididymis 4 (HE4), and CA72-4 levels and Risk of Ovarian Malignancy Algorithm (ROMA) values for differential diagnosis of malignan...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Kyung-Hwa, Kim, Hyung-Hoi, Kwon, Byung Su, Suh, Dong Soo, Joo, Jong Kil, Kim, Ki Hyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Laboratory Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713655/
https://www.ncbi.nlm.nih.gov/pubmed/31432638
http://dx.doi.org/10.3343/alm.2020.40.1.40
_version_ 1783446900030046208
author Shin, Kyung-Hwa
Kim, Hyung-Hoi
Kwon, Byung Su
Suh, Dong Soo
Joo, Jong Kil
Kim, Ki Hyung
author_facet Shin, Kyung-Hwa
Kim, Hyung-Hoi
Kwon, Byung Su
Suh, Dong Soo
Joo, Jong Kil
Kim, Ki Hyung
author_sort Shin, Kyung-Hwa
collection PubMed
description BACKGROUND: Tumor markers are useful for detection and preoperative evaluation of ovarian tumors. We evaluated the clinical usefulness of cancer antigen (CA) 125, human epididymis 4 (HE4), and CA72-4 levels and Risk of Ovarian Malignancy Algorithm (ROMA) values for differential diagnosis of malignant and borderline tumors among suspected ovarian tumors, and the effects of endometriosis on these tumor markers. METHODS: In a total of 266 patients (213, 14, and 39 with benign, borderline and malignant tumors, respectively), CA125, HE4, and CA72-4 levels were measured, and ROMA values were calculated. Medians of each marker were compared among the three groups. The area under the ROC curve (AUC), sensitivity, and specificity were calculated to analyze the diagnostic performance of each marker. RESULTS: All markers were significantly higher in the malignant group than in the benign group. HE4 levels and ROMA values were significantly higher in the malignant group than in the borderline group. ROMA value had the highest AUC for distinguishing the malignant and borderline groups from the benign group in premenopausal (0.773) and postmenopausal (0.927) patients. CA125 level was significantly higher in patients with endometriosis than in those without (P<0.001), whereas HE4 and CA72-4 levels were not affected by endometriosis (P=0.128 and 0.271, respectively). CONCLUSIONS: ROMA value is the best marker to distinguish malignant and borderline tumors from benign tumors in pre- and postmenopausal patients. HE4 and CA72-4 levels provide information on possible CA125 elevation due to endometriosis.
format Online
Article
Text
id pubmed-6713655
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Society for Laboratory Medicine
record_format MEDLINE/PubMed
spelling pubmed-67136552020-01-01 Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis Shin, Kyung-Hwa Kim, Hyung-Hoi Kwon, Byung Su Suh, Dong Soo Joo, Jong Kil Kim, Ki Hyung Ann Lab Med Original Article BACKGROUND: Tumor markers are useful for detection and preoperative evaluation of ovarian tumors. We evaluated the clinical usefulness of cancer antigen (CA) 125, human epididymis 4 (HE4), and CA72-4 levels and Risk of Ovarian Malignancy Algorithm (ROMA) values for differential diagnosis of malignant and borderline tumors among suspected ovarian tumors, and the effects of endometriosis on these tumor markers. METHODS: In a total of 266 patients (213, 14, and 39 with benign, borderline and malignant tumors, respectively), CA125, HE4, and CA72-4 levels were measured, and ROMA values were calculated. Medians of each marker were compared among the three groups. The area under the ROC curve (AUC), sensitivity, and specificity were calculated to analyze the diagnostic performance of each marker. RESULTS: All markers were significantly higher in the malignant group than in the benign group. HE4 levels and ROMA values were significantly higher in the malignant group than in the borderline group. ROMA value had the highest AUC for distinguishing the malignant and borderline groups from the benign group in premenopausal (0.773) and postmenopausal (0.927) patients. CA125 level was significantly higher in patients with endometriosis than in those without (P<0.001), whereas HE4 and CA72-4 levels were not affected by endometriosis (P=0.128 and 0.271, respectively). CONCLUSIONS: ROMA value is the best marker to distinguish malignant and borderline tumors from benign tumors in pre- and postmenopausal patients. HE4 and CA72-4 levels provide information on possible CA125 elevation due to endometriosis. The Korean Society for Laboratory Medicine 2020-01 2019-08-19 /pmc/articles/PMC6713655/ /pubmed/31432638 http://dx.doi.org/10.3343/alm.2020.40.1.40 Text en © The Korean Society for Laboratory Medicine http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Shin, Kyung-Hwa
Kim, Hyung-Hoi
Kwon, Byung Su
Suh, Dong Soo
Joo, Jong Kil
Kim, Ki Hyung
Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis
title Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis
title_full Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis
title_fullStr Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis
title_full_unstemmed Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis
title_short Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis
title_sort clinical usefulness of cancer antigen (ca) 125, human epididymis 4, and ca72-4 levels and risk of ovarian malignancy algorithm values for diagnosing ovarian tumors in korean patients with and without endometriosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713655/
https://www.ncbi.nlm.nih.gov/pubmed/31432638
http://dx.doi.org/10.3343/alm.2020.40.1.40
work_keys_str_mv AT shinkyunghwa clinicalusefulnessofcancerantigenca125humanepididymis4andca724levelsandriskofovarianmalignancyalgorithmvaluesfordiagnosingovariantumorsinkoreanpatientswithandwithoutendometriosis
AT kimhyunghoi clinicalusefulnessofcancerantigenca125humanepididymis4andca724levelsandriskofovarianmalignancyalgorithmvaluesfordiagnosingovariantumorsinkoreanpatientswithandwithoutendometriosis
AT kwonbyungsu clinicalusefulnessofcancerantigenca125humanepididymis4andca724levelsandriskofovarianmalignancyalgorithmvaluesfordiagnosingovariantumorsinkoreanpatientswithandwithoutendometriosis
AT suhdongsoo clinicalusefulnessofcancerantigenca125humanepididymis4andca724levelsandriskofovarianmalignancyalgorithmvaluesfordiagnosingovariantumorsinkoreanpatientswithandwithoutendometriosis
AT joojongkil clinicalusefulnessofcancerantigenca125humanepididymis4andca724levelsandriskofovarianmalignancyalgorithmvaluesfordiagnosingovariantumorsinkoreanpatientswithandwithoutendometriosis
AT kimkihyung clinicalusefulnessofcancerantigenca125humanepididymis4andca724levelsandriskofovarianmalignancyalgorithmvaluesfordiagnosingovariantumorsinkoreanpatientswithandwithoutendometriosis